Compare Aehr Test Systems (AEHR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aehr Test Systems vs Regeneron Pharmaceuticals Inc — how do they compare? Aehr Test Systems trades at $65.66 (market cap $2.11B), while Regeneron Pharmaceuticals Inc trades at $662.43 (market cap $70.90B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 33.6× Aehr Test Systems's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Aehr Test Systems pays none. Which is the better fit depends on your goals.
| AEHR | REGN | |
|---|---|---|
Market Cap | $2.11B | $70.90B |
Sector | Technology | Health |
52-Week High | $116.58 | $812.27 |
52-Week Low | $13.29 | $542.52 |
Enterprise Value | $2.08B | $64.85B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEHR trades at $72.33, up 3.38% today, with a bullish technical signal driven by oversold RSI readings near 24.5, though moving averages remain bearish. The company reported Q1 2026 EPS of -$0.05, beating expectations, but maintains negative profitability margins and cash flow. Recent news highlights strong order growth from AI and silicon photonics customers, including a follow-on system order announced June 17, 2026.
Outlook is mixed: robust order book and AI sector tailwinds support growth, but high P/S of 46.6 and persistent losses pose valuation risks. Analyst consensus is cautious with 33% buy ratings. Key risks include execution on orders and cash burn.
Regeneron (REGN) trades at $676.23, up 3.36% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $9.47 exceeding the $8.91 forecast. Revenue grew to $14.34B in 2025, with a net income margin of 29.65%. Recent FDA acceptance of cemdisiran for gMG and inclusion in a manufacturing review pilot program highlight positive regulatory developments.
Outlook remains positive given earnings momentum and analyst consensus, but risks include regulatory scrutiny and competitive pressures. The consensus price target of $778.29 implies 15% upside, supported by 32 buy ratings and no sells. However, legal investigations and reliance on key drug portfolios warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aehr Test Systems
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
